Literature DB >> 12525154

Identification of amino acids in the nicotinic acetylcholine receptor agonist binding site and ion channel photolabeled by 4-[(3-trifluoromethyl)-3H-diazirin-3-yl]benzoylcholine, a novel photoaffinity antagonist.

David C Chiara1, Jonathan C Trinidad, Dong Wang, Michael R Ziebell, Deirdre Sullivan, Jonathan B Cohen.   

Abstract

[(3)H]4-[(3-trifluoromethyl)-3H-diazirin-3-yl]benzoylcholine (TDBzcholine) was synthesized and used as a photoaffinity probe to map the orientation of an aromatic choline ester within the agonist binding sites of the Torpedo nicotinic acetylcholine receptor (nAChR). TDBzcholine acts as a nAChR competitive antagonist that binds at equilibrium with equal affinity to both agonist sites (K(D) approximately 10 microM). Upon UV irradiation (350 nm), nAChR-rich membranes equilibrated with [(3)H]TDBzcholine incorporate (3)H into the alpha, gamma, and delta subunits in an agonist-inhibitable manner. The specific residues labeled by [(3)H]TDBzcholine were determined by N-terminal sequence analysis of subunit fragments produced by enzymatic cleavage and purified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and/or reversed-phase high-performance liquid chromatography. For the alpha subunit, [(3)H]TDBzcholine photoincorporated into alphaCys-192, alphaCys-193, and alphaPro-194. For the gamma and delta subunits, [(3)H]TDBzcholine incorporated into homologous leucine residues, gammaLeu-109 and deltaLeu-111. The photolabeling of these amino acids suggests that when the antagonist TDBzcholine occupies the agonist binding sites, the Cys-192-193 disulfide and Pro-194 from the alpha subunit Segment C are oriented toward the agonist site and are in proximity to gammaLeu-109/deltaLeu-111 in Segment E, a conclusion consistent with the structure of the binding site in the molluscan acetylcholine binding protein, a soluble protein that is homologous to the nAChR extracellular domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525154     DOI: 10.1021/bi0269815

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Picrotoxin-like channel blockers of GABAA receptors.

Authors:  Richard W Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

2.  Synthesis and pharmacological evaluation of neurosteroid photoaffinity ligands.

Authors:  Pavel Y Savechenkov; David C Chiara; Rooma Desai; Alexander T Stern; Xiaojuan Zhou; Alexis M Ziemba; Andrea L Szabo; Yinghui Zhang; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik
Journal:  Eur J Med Chem       Date:  2017-04-21       Impact factor: 6.514

3.  Molecular modeling of the GABA(C) receptor ligand-binding domain.

Authors:  Neil J Harrison; Sarah C R Lummis
Journal:  J Mol Model       Date:  2005-10-26       Impact factor: 1.810

Review 4.  Photoaffinity labeling of nicotinic receptors: diversity of drug binding sites!

Authors:  Ayman K Hamouda; Selwyn S Jayakar; David C Chiara; Jonathan B Cohen
Journal:  J Mol Neurosci       Date:  2013-10-26       Impact factor: 3.444

5.  Time-resolved photolabeling of the nicotinic acetylcholine receptor by [3H]azietomidate, an open-state inhibitor.

Authors:  David C Chiara; Filbert H Hong; Enrique Arevalo; S Shaukat Husain; Keith W Miller; Stuart A Forman; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2009-02-13       Impact factor: 4.436

6.  [(3)H]chlorpromazine photolabeling of the torpedo nicotinic acetylcholine receptor identifies two state-dependent binding sites in the ion channel.

Authors:  David C Chiara; Ayman K Hamouda; Michael R Ziebell; Luis A Mejia; Galo Garcia; Jonathan B Cohen
Journal:  Biochemistry       Date:  2009-10-27       Impact factor: 3.162

7.  Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor.

Authors:  Ayman K Hamouda; Tilia Kimm; Jonathan B Cohen
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.